Idvynso, Merck’s Once-Daily HIV Pill, Wins FDA Approval

Key Takeaways

• Idvynso is the first non‑INSTI, tenofovir‑free two‑drug regimen
• Phase III trials showed non‑inferior efficacy versus Biktarvy
• Only 1% of switch patients experienced viral rebound at Week 48
• Idvynso will be available in U.S. pharmacies after May 11

Pulse Analysis

Merck’s Idvynso marks a pivotal moment in HIV treatment, introducing the first non‑integrase strand transfer inhibitor (INSTI) regimen that omits tenofovir. By pairing doravirine, a non‑nucleoside reverse transcriptase inhibitor, with islatravir, a next‑generation nucleoside analog, the once‑daily tablet simplifies therapy for patients already achieving viral suppression. This approval not only broadens the switch‑option landscape but also aligns with a growing industry trend toward two‑drug regimens that aim to reduce toxicity, drug‑drug interactions, and overall pill burden.

The pivotal data came from two randomized Phase III studies involving over 700 participants who transitioned from stable regimens, including Gilead’s Biktarvy. Both trials demonstrated that Idvynso maintained viral suppression in more than 90% of patients, with only 1% experiencing a rebound to 50 copies/mL or higher at Week 48—mirroring the performance of the three‑drug comparator. Safety profiles were comparable across age, sex, and racial subgroups, reinforcing the regimen’s suitability for a diverse adult population, including older adults who often face comorbidities and polypharmacy concerns.

Idvynso’s entry intensifies competition in a market dominated by INSTI‑based combos, prompting rivals like ViiV Healthcare and Gilead to accelerate long‑acting and novel mechanisms such as capsid inhibitors and next‑generation integrase inhibitors. As payers and clinicians prioritize adherence and cost‑effectiveness, a tenofovir‑free, two‑drug option could reshape formulary decisions and drive price negotiations. Moreover, Merck’s success may spur further investment in streamlined HIV therapies, reinforcing a broader shift toward personalized, low‑pill‑count solutions that sustain viral control while improving quality of life for millions living with HIV.